Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonDividends Paid - PreferredFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amdocs (DOX) Gains from Sales and Divestitures: 2009-2025

  • Amdocs' Gains from Sales and Divestitures fell 14.26% to $932,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $932,000, marking a year-over-year decrease of 14.26%. This contributed to the annual value of $932,000 for FY2025, which is 9.01% up from last year.
  • Amdocs' Gains from Sales and Divestitures amounted to $932,000 in Q3 2025, which was down 14.26% from $1.1 million recorded in Q3 2024.
  • In the past 5 years, Amdocs' Gains from Sales and Divestitures registered a high of $1.1 million during Q3 2024, and its lowest value of $880,000 during Q3 2021.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $1.1 million (2023), whereas its average is $1.0 million.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first climbed by 22.73% in 2022, then fell by 14.26% in 2025.
  • Quarterly analysis of 5 years shows Amdocs' Gains from Sales and Divestitures stood at $880,000 in 2021, then rose by 22.73% to $1.1 million in 2022, then grew by 0.19% to $1.1 million in 2023, then rose by 0.46% to $1.1 million in 2024, then dropped by 14.26% to $932,000 in 2025.
  • Its Gains from Sales and Divestitures was $932,000 in Q3 2025, compared to $1.1 million in Q3 2024 and $1.1 million in Q3 2023.